MHY-1685 is a mammalian target of rapamycin (mTOR) inhibitor and a senescence inhibitor that can rejuvenate senile hCSCs by modulating autophagy.

Fipexide (Attentil, Vigilor), a psychoactive drug of the piperazine chemical class, was developed in Italy in 1983. It was served as a nootropic drug in France and Italy, mainly for the therapy of senile dementia, but is no longer in common use because of the occurrence of rare drug side-effects including hepatitis and fever.

Nicergoline-13C-d3 the 13C and deuterated compound of Nicergoline. Nicergoline has a CAS number of 27848-84-6. Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins.

β-Amyloid (12-28) (TFA), a peptide fragment of the β-amyloid protein (β1-42)—a 42 amino acid protein primarily found in senile plaque cores—exhibits aggregation properties. This compound holds significance for research into Alzheimer’s disease, highlighting its potential utility in understanding the disease's pathology [1].

MCI-225 is a norepinephrine reuptake/5-HT3/5-HT reuptake inhibitor. MCI-225 could be effective in the treatment of senile dementia of the Alzheimer type, which is accompanied with both deficit in the BF-cortex cholinergic neuron and cerebral glucose hypom

β-amyloid (12-28) TFA, a peptide fragment of β-amyloid protein (β1-42), is the major component of senile plaque cores. β-amyloid (12-28) has aggregation properties and the potential for Alzheimer’s disease research.

Nicergoline (Nicergolinum) is an ergot derivative used to treat senile dementia and other disorders with vascular origins.

Amyloid-β (1-42) (Aβ42) is a neurotoxic 42-amino acid protein fragment found in amyloid plaques in postmortem cerebral cortex from patients with Alzheimer's disease.1,2,3Aggregation of Aβ42 results in the formation of neurotoxic fibrils or globular oligomers.1Aβ42 accumulates in the brain of many transgenic mouse models of Alzheimer's disease and, in many models, the onset of amyloid deposition positively correlates with deficits in spatial learning and memory.4 1.Wolfe, M.S.Therapeutic strategies for Alzheimer's diseaseNat. Rev. Drug Discov.1(11)859-866(2002) 2.Iwatsubo, T., Odaka, A., Suzuki, N., et al.Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron13(1)45-53(1994) 3.Hardy, J.A., and Higgins, G.A.Alzheimer's disease: The amyloid cascade hypothesisScience256(5054)184-185(1992) 4.Jankowsky, J.L., and Zheng, H.Practical considerations for choosing a mouse model of Alzheimer's diseaseMol. Neurodegener.12(1)89(2017)

The amyloid β-protein is a 39- to 43-amino acid polypeptide that is the primary constituent of senile plaques and cerebrovascular deposits in Alzheimer's disease and Down's syndrome. Additionally it acts as an inhibitor of the ubiquitin-dependent protein degradation in vitro.

Timtraxanib (AVI-3207) is a potent and specific inhibitor of VEGF-2, offering great potential for investigating senile macular degeneration.

TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease.

Rosiridin (6'-O-Deacetylrosiridoside C) has cardioprotective activity.

Nicergoline tartrate is a bioactive chemical.